Molecular tumor board—renal cell carcinoma Molekulares Tumorboard – Nierenzellkarzinom
Grünwald V, Doehn C, Goebell P (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Journal
DOI: 10.1007/s00120-019-0965-7
Abstract
The introduction of molecular targeted agents has fundamentally changed the treatment of metastatic renal cell carcinoma. A first wave of development was based on the improved understanding of tumor biology since the discovery of the importance of the von Hippel-Lindau gene as the key driver of the disease and paved the way for antiangiogenic agents. Of relevance is the overexpression of proangiogenic and proliferation-promoting factors (VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor) as well as an overactivation of the PI3K-Akt signaling pathway: the target structure is the “mammalian target of rapamycin” (mTOR) molecule, which is involved in the regulation of cell proliferative processes. VEGF-, PDGF-, and mTOR-signals and signaling pathways are central targets of current targeted substances. A second wave is certainly to be seen in the development of therapeutic approaches with the targeted activation and modulation of the immune system, which has brought “immunotherapy” back into the focus of interest. Central development is the application of immune-checkpoint inhibitors, with the help of which (re-)activation of the cellular defense, especially of T cells, takes place, which per se holds the potential of a cytoreductive therapy by killing the tumor cells. Even though the prognosis has improved significantly due to the rapid development of recent years, treatment remains challenging as most patients experience progress, and long-term survival is only achieved in about 20% of cases because some patients are primarily refractory or do not respond. The more intensive interlocking of molecular biology, pathology, clinical research, and interdisciplinary uro-oncology, as is the claim of molecular tumor boards, can contribute to the individual selection of a suitable therapy strategy and, thus, establish the latest findings and developments for the benefit of patients in the clinic.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Grünwald, V., Doehn, C., & Goebell, P. (2019). Molecular tumor board—renal cell carcinoma Molekulares Tumorboard – Nierenzellkarzinom. Urologe. https://doi.org/10.1007/s00120-019-0965-7
MLA:
Grünwald, V., C. Doehn, and Peter Goebell. "Molecular tumor board—renal cell carcinoma Molekulares Tumorboard – Nierenzellkarzinom." Urologe (2019).
BibTeX: Download